The EURO EWING 2012 phase III trial reported that adding zoledronic acid to standard chemotherapy improved key outcomes in patients with Ewing sarcoma, according to trial investigators. The randomized study evaluated bisphosphonate adjunct therapy alongside established cytotoxic regimens and found measurable benefits that argue for revisiting treatment protocols in this pediatric and young‑adult cancer. Investigators note that integration into practice will depend on full dataset review, toxicity profiling, and regulatory discussions in different jurisdictions.